| Autor: |
Bandell, Allyn, Ambrose, Christopher S., Maniaci, Jon, Wojtczak, Henry |
| Předmět: |
|
| Zdroj: |
Expert Review of Vaccines; Jun2021, Vol. 20 Issue 6, p717-728, 12p |
| Abstrakt: |
Asthma is one of the most common chronic respiratory conditions worldwide and can be exacerbated by influenza. Findings from early trials demonstrated a higher risk of medically significant wheezing in otherwise healthy young children (aged 6 − 23 months) following administration of the Ann Arbor-backbone live attenuated influenza vaccine (LAIV-AA). In more recent years, several additional studies have investigated the safety of LAIV-AA in older children (2 − 17 years of age) and adults with asthma or prior wheezing, but these findings have not yet been systematically evaluated. We conducted a systematic literature review to assess and synthesize the evidence from all available studies on the safety of LAIV-AA in people aged 2 − 49 years with a diagnosis of asthma or recurrent wheezing. Fourteen studies over 20 years, involving a total of 1.2 million participants, provided evidence that LAIV-AA was well tolerated with no safety concerns in individuals aged 2 − 49 years with a diagnosis of asthma or recurrent wheezing. These data can help inform guidelines for use of LAIV-AA in children and adults with a history of asthma or recurrent wheezing. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
